- Home
- ANAB vs NX Comparison
ANAB vs NX Comparison
Compare ANAB & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NX
- Stock Information
- Founded
- ANAB 2005
- NX 1927
- Country
- ANAB United States
- NX United States
- Employees
- ANAB N/A
- NX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NX Metal Fabrications
- Sector
- ANAB Health Care
- NX Industrials
- Exchange
- ANAB Nasdaq
- NX Nasdaq
- Market Cap
- ANAB 659.6M
- NX 660.6M
- IPO Year
- ANAB 2017
- NX N/A
- Fundamental
- Price
- ANAB $31.83
- NX $14.47
- Analyst Decision
- ANAB Buy
- NX
- Analyst Count
- ANAB 10
- NX 0
- Target Price
- ANAB $50.63
- NX N/A
- AVG Volume (30 Days)
- ANAB 749.6K
- NX 706.8K
- Earning Date
- ANAB 11-04-2025
- NX 09-04-2025
- Dividend Yield
- ANAB N/A
- NX 2.21%
- EPS Growth
- ANAB N/A
- NX N/A
- EPS
- ANAB N/A
- NX N/A
- Revenue
- ANAB $123,164,000.00
- NX $1,839,956,000.00
- Revenue This Year
- ANAB $11.40
- NX $46.73
- Revenue Next Year
- ANAB $8.17
- NX $0.48
- P/E Ratio
- ANAB N/A
- NX N/A
- Revenue Growth
- ANAB 304.17
- NX 70.18
- 52 Week Low
- ANAB $12.21
- NX $13.22
- 52 Week High
- ANAB $36.54
- NX $32.23
- Technical
- Relative Strength Index (RSI)
- ANAB 71.43
- NX 35.07
- Support Level
- ANAB $29.49
- NX $14.22
- Resistance Level
- ANAB $32.24
- NX $14.96
- Average True Range (ATR)
- ANAB 2.08
- NX 0.50
- MACD
- ANAB 0.81
- NX 0.19
- Stochastic Oscillator
- ANAB 82.04
- NX 66.95
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.